04/22/2026
๐จ ๐ฃ๐ต๐ฎ๐๐ฒ ๐ฏ ๐จ๐๐ง๐๐ ๐๐ง๐ ๐ & ๐๐ ๐๐ฎ๐๐ฎ ๐จ๐ฝ๐ฑ๐ฎ๐๐ฒ ๐จ
New data published last month in Neurology and Therapy (March 9) reinforces why we advocate for high-efficacy intervention early in the disease course for Relapsing MS (RMS).
A pooled analysis of the Phase 3 ULTIMATE I & II studies for BRIUMVI (ublituximab-xiiy) demonstrated a 95.6% reduction in Gd+ T1 lesions over 96 weeks compared to standard oral therapies. Another observed benefit over teriflunomide was that BRIUMVI patients were nearly 5 times more likely to achieve NEDA-3 during weeks 24โ96.
At LUX Infusion, we see the critical importance of optimizing therapy in challenging cases of RMS, so we work hard to remove the logistical, financial, and clinical barriers that might prevent patients from accessing early, high-efficacy treatment.
Link in the comments to learn more!